Literature DB >> 12970845

Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect.

Linda L Bachinski1, Bjarne Udd, Giovanni Meola, Valeria Sansone, Guillaume Bassez, Bruno Eymard, Charles A Thornton, Richard T Moxley, Peter S Harper, Mark T Rogers, Karin Jurkat-Rott, Frank Lehmann-Horn, Thomas Wieser, Josep Gamez, Carmen Navarro, Armand Bottani, Andre Kohler, Mark D Shriver, Riitta Sallinen, Maija Wessman, Shanxiang Zhang, Fred A Wright, Ralf Krahe.   

Abstract

Myotonic dystrophy (DM), the most common form of muscular dystrophy in adults, is a clinically and genetically heterogeneous neuromuscular disorder. DM is characterized by autosomal dominant inheritance, muscular dystrophy, myotonia, and multisystem involvement. Type 1 DM (DM1) is caused by a (CTG)(n) expansion in the 3' untranslated region of DMPK in 19q13.3. Multiple families, predominantly of German descent and with clinically variable presentation that included proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1 mutation, showed linkage to the 3q21 region and were recently shown to segregate a (CCTG)(n) expansion mutation in intron 1 of ZNF9. Here, we present linkage to 3q21 and mutational confirmation in 17 kindreds of European origin with PROMM and proximal myotonic dystrophy, from geographically distinct populations. All patients have the DM2 (CCTG)(n) expansion. To study the evolution of this mutation, we constructed a comprehensive physical map of the DM2 region around ZNF9. High-resolution haplotype analysis of disease chromosomes with five microsatellite and 22 single-nucleotide polymorphism markers around the DM2 mutation identified extensive linkage disequilibrium and a single shared haplotype of at least 132 kb among patients from the different populations. With the exception of the (CCTG)(n) expansion, the available markers indicate that the DM2 haplotype is identical to the most common haplotype in normal individuals. This situation is reminiscent of that seen in DM1. Taken together, these data suggest a single founding mutation in DM2 patients of European origin. We estimate the age of the founding haplotype and of the DM2 (CCTG) expansion mutation to be approximately 200-540 generations.

Entities:  

Mesh:

Year:  2003        PMID: 12970845      PMCID: PMC1180606          DOI: 10.1086/378566

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  51 in total

Review 1.  Estimating allele age.

Authors:  M Slatkin; B Rannala
Journal:  Annu Rev Genomics Hum Genet       Date:  2000       Impact factor: 8.929

2.  Physical mapping of mouse collagen genes on chromosome 10 by high-resolution FISH.

Authors:  R Sallinen; A Latvanlehto; A P Kvist; M Rehn; I Eerola; M L Chu; P Bonaldo; B Saitta; G M Bressan; T Pihlajaniemi; E Vuorio; A Palotie; M Wessman; N Horelli-Kuitunen
Journal:  Mamm Genome       Date:  2001-05       Impact factor: 2.957

3.  Proof of genetic heterogeneity in the proximal myotonic myopathy syndrome (PROMM) and its relationship to myotonic dystrophy type 2 (DM2).

Authors:  W Kress; B Mueller-Myhsok; K Ricker; C Schneider; M C Koch; K V Toyka; C R Mueller; T Grimm
Journal:  Neuromuscul Disord       Date:  2000-10       Impact factor: 4.296

4.  New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC).

Authors: 
Journal:  Neurology       Date:  2000-03-28       Impact factor: 9.910

5.  A family with PROMM not linked to the recently mapped PROMM locus DM2.

Authors:  T Wieser; D Bönsch; K Eger; W Schulte-Mattler; S Zierz
Journal:  Neuromuscul Disord       Date:  2000-02       Impact factor: 4.296

6.  PGD in the lab for triplet repeat diseases - myotonic dystrophy, Huntington's disease and Fragile-X syndrome.

Authors:  K Sermon; S Seneca; M De Rycke; V Goossens; H Van de Velde; A De Vos; P Platteau; W Lissens; A Van Steirteghem; I Liebaers
Journal:  Mol Cell Endocrinol       Date:  2001-10-22       Impact factor: 4.102

7.  Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.

Authors:  C L Liquori; K Ricker; M L Moseley; J F Jacobsen; W Kress; S L Naylor; J W Day; L P Ranum
Journal:  Science       Date:  2001-08-03       Impact factor: 47.728

8.  Proximal myotonic myopathy: clinical, electrophysiological and pathological findings in a family.

Authors:  A Kohler; P Burkhard; S Hefft; A Bottani; G P Pizzolato; M R Magistris
Journal:  Eur Neurol       Date:  2000       Impact factor: 1.710

9.  [Proximal myotonial myopathy (PROMM): clinical and histology study].

Authors:  G Bassez; S Attarian; P Laforêt; J P Azulay; A Rouche; X Ferrer; J A Urtizberea; J F Pellissier; D Duboc; M Fardeau; J Pouget; B Eymard
Journal:  Rev Neurol (Paris)       Date:  2001-02       Impact factor: 2.607

10.  Genetic mapping of a second myotonic dystrophy locus.

Authors:  L P Ranum; P F Rasmussen; K A Benzow; M D Koob; J W Day
Journal:  Nat Genet       Date:  1998-06       Impact factor: 38.330

View more
  53 in total

1.  Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2.

Authors:  Olayinka Raheem; Shodimu-Emmanuel Olufemi; Linda L Bachinski; Anna Vihola; Mario Sirito; Jeanette Holmlund-Hampf; Hannu Haapasalo; Yi-Ping Li; Bjarne Udd; Ralf Krahe
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

2.  High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany.

Authors:  T Suominen; B Schoser; O Raheem; S Auvinen; M Walter; R Krahe; H Lochmüller; W Kress; B Udd
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

3.  Relative risks for comorbidities associated with myotonic dystrophy: A population-based analysis.

Authors:  Nicholas E Johnson; Diana Abbott; Lisa A Cannon-Albright
Journal:  Muscle Nerve       Date:  2015-08-26       Impact factor: 3.217

Review 4.  The muscular dystrophies: from genes to therapies.

Authors:  Richard M Lovering; Neil C Porter; Robert J Bloch
Journal:  Phys Ther       Date:  2005-12

Review 5.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

Review 6.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

Review 7.  Recent advances in myotonic dystrophy type 2.

Authors:  Christina M Ulane; Sarah Teed; Jacinda Sampson
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

8.  A Z-DNA sequence reduces slipped-strand structure formation in the myotonic dystrophy type 2 (CCTG) x (CAGG) repeat.

Authors:  Sharon F Edwards; Mario Sirito; Ralf Krahe; Richard R Sinden
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

9.  Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

Authors:  Benedikt Schoser; Lubov Timchenko
Journal:  Curr Genomics       Date:  2010-04       Impact factor: 2.236

Review 10.  Eccentric exercise in aging and diseased skeletal muscle: good or bad?

Authors:  Richard M Lovering; Susan V Brooks
Journal:  J Appl Physiol (1985)       Date:  2013-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.